Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs EOX in advanced gastric cancer
NCT02395640Phase 3Completed
- Sponsor
- Fudan University
- Start
- Mar 2015
- Primary completion
- Feb 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, capecitabine in gastric cancer (GC), sponsored by Fudan University. Started Mar 2015; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02395640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395640.